This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Althaus, J. S. Articles by Von Voigtlander, P. F. Search for Related Content PubMed PubMed Citation Articles by Althaus, J. S. Articles by Von Voigtlander, P. F.

Enhancement of Anesthetic Effect of Halothane by Spiradoline, A Selective -Agonist

Received from the University of Virginia Medical Center, Charlottesville, Virginia, and the Upjohn Company, Kalamazoo, Michigan.

Abstract

Reduction in the anesthetic requirement of halothane by narcotics has been studied extensively in humans and animals. Problems of respiratory depression, cardiovascular depression, muscle rigidity, and abuse potential make narcotics less than ideal as supplements to general anesthesia with inhalational agents. Spiradoline, a clinical candidate, is a highly potent and selective -agonist. As such it was considered important to study the effects of spiradoline on the minimum anesthetic concentration (MAC) of halothane required to block responses to noxious stimulation. The results of these experiments in rats showed a dose and plasma concentration-dependent reduction in halothane MAC over a wide range of subcutaneous doses of spiradoline (0.03 to 300 mg/kg). A maximum MAC reduction of 70% was obtained. Plasma levels of spiradoline (6 to 1800 ng/ml) were linearly related to dose. Measurement of blood pressure, heart rate, and Pco₂ determined over the course of each experiment showed minor variations which would be acceptable if observed in a clinical setting. If is concluded that spiradoline has promise as an anesthetic supplement.

Key Words: ANESTHETICS, VOLATILE—halothane • RECEPTORS, OPIOID— • ANALGESICS—spiradoline